This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
pulmonary hypertension | 720 |
pulmonary fibrosis | 550 |
lung disease | 511 |
pulmonary disease | 466 |
lung injury | 420 |
idiopathic pulmonary | 379 |
chronic obstructive | 376 |
pulmonary vascular | 367 |
respiratory distress | 363 |
obstructive pulmonary | 352 |
intensive care | 350 |
acute respiratory | 330 |
lung cancer | 322 |
mechanical ventilation | 321 |
pulmonary artery | 289 |
interstitial pneumonia | 284 |
distress syndrome | 278 |
lung function | 272 |
respiratory tract | 250 |
nitric oxide | 250 |
respiratory failure | 242 |
pulmonary edema | 234 |
cystic fibrosis | 231 |
pulmonary embolism | 226 |
pulmonary arterial | 222 |
fi brosis | 220 |
acute lung | 217 |
type ii | 213 |
risk factors | 202 |
vascular resistance | 195 |
epithelial cells | 194 |
alveolar macrophages | 192 |
cardiac output | 191 |
primary pulmonary | 188 |
smooth muscle | 187 |
lung diseases | 184 |
may also | 181 |
care unit | 180 |
liver transplantation | 179 |
mg kg | 178 |
right ventricular | 178 |
pulmonary function | 177 |
interstitial lung | 176 |
heart failure | 175 |
blood flow | 169 |
growth factor | 164 |
see chapter | 162 |
pulmonary fi | 156 |
bone marrow | 155 |
lymph nodes | 154 |
cardiac surgery | 142 |
septic shock | 142 |
critically ill | 142 |
heart disease | 139 |
acute exacerbation | 137 |
copd patients | 134 |
gas exchange | 134 |
pulmonary arteries | 134 |
induced pulmonary | 134 |
respiratory system | 133 |
bronchoalveolar lavage | 130 |
pleural effusion | 128 |
bronchiolitis obliterans | 127 |
blood pressure | 127 |
endothelial cells | 122 |
lung transplantation | 122 |
arterial pressure | 120 |
chest wall | 118 |
diffuse alveolar | 117 |
lung tissue | 116 |
organizing pneumonia | 115 |
oxidative stress | 114 |
connective tissue | 108 |
two groups | 106 |
lung biopsy | 106 |
arterial hypertension | 104 |
mean age | 102 |
fi ndings | 102 |
mortality rate | 102 |
alveolar damage | 100 |
computed tomography | 99 |
heart rate | 99 |
congenital heart | 98 |
chronic lung | 98 |
spontaneous pneumothorax | 98 |
mm hg | 97 |
chest pain | 97 |
acute pulmonary | 97 |
pulmonary complications | 97 |
inflammatory response | 97 |
united states | 96 |
renal failure | 95 |
immune response | 95 |
pulmonary surfactant | 92 |
right heart | 92 |
lung parenchyma | 91 |
type i | 90 |
histologic study | 89 |
pulmonary circulation | 88 |
airway obstruction | 88 |
viral infections | 87 |
may occur | 87 |
respiratory disease | 87 |
pulmonary alveolar | 86 |
stem cell | 85 |
control group | 85 |
pulmonary blood | 85 |
mechanically ventilated | 84 |
important role | 84 |
arterial blood | 83 |
pulmonary rehabilitation | 83 |
induced lung | 83 |
side effects | 82 |
marrow transplantation | 81 |
organ failure | 81 |
associated conditions | 81 |
severe acute | 80 |
ill patients | 80 |
airway pressure | 80 |
surfactant protein | 80 |
cardiac rehabilitation | 79 |
vascular disease | 79 |
animal models | 79 |
see also | 79 |
necrosis factor | 79 |
possible associated | 78 |
icu patients | 77 |
human beings | 76 |
alveolar proteinosis | 76 |
right ventricle | 75 |
pulmonary oedema | 75 |
signifi cant | 75 |
liver disease | 74 |
clinical trials | 74 |
prospective study | 74 |
coronary artery | 74 |
risk factor | 73 |
inflammatory cells | 73 |
hiv aids | 73 |
cell transplantation | 73 |
cigarette smoke | 72 |
membrane oxygenation | 72 |
left ventricular | 72 |
specimen preparation | 72 |
inhaled nitric | 71 |
human lung | 71 |
extracorporeal membrane | 71 |
increased risk | 71 |
clinical signs | 71 |
tidal volume | 71 |
controlled trial | 70 |
rheumatoid arthritis | 70 |
infl ammation | 69 |
myocardial infarction | 69 |
tumor necrosis | 69 |
muscle cells | 69 |
immune responses | 69 |
pleural effusions | 68 |
pneumocystis carinii | 68 |
doc id | 68 |
expected findings | 68 |
apache ii | 68 |
acute pe | 68 |
cord uid | 68 |
bacterial pneumonia | 68 |
blood vessels | 68 |
nasal cavity | 68 |
may cause | 68 |
case report | 67 |
rhodococcus equi | 67 |
alveolar walls | 67 |
virus infection | 66 |
chest radiograph | 66 |
differential diagnosis | 66 |
systematic review | 66 |
pulmonary infections | 66 |
aids related | 65 |
electron microscopy | 65 |
respiratory symptoms | 64 |
transforming growth | 64 |
related terms | 64 |
ml kg | 64 |
physical activity | 64 |
may result | 63 |
pulmonary vasoconstriction | 63 |
bacterial infections | 63 |
fl uid | 63 |
group i | 63 |
lung volume | 63 |
lower respiratory | 63 |
high risk | 63 |
fungal infections | 62 |
multiple organ | 62 |
central venous | 62 |
dl co | 62 |
interstitial fibrosis | 62 |
pulmonary syndrome | 62 |
cell count | 62 |
chronic bronchitis | 62 |
upper respiratory | 62 |
aids patients | 61 |
significantly higher | 61 |
adult respiratory | 61 |
dendritic cells | 61 |
upper airway | 61 |
respiratory syndrome | 61 |
hypersensitivity pneumonitis | 61 |
mycobacterium tuberculosis | 61 |
alveolar type | 61 |
hematopoietic stem | 60 |
alveolar epithelium | 60 |
airway inflammation | 60 |
ii cells | 60 |
critical care | 60 |
pg ml | 60 |
statistically significant | 60 |
gene expression | 60 |
septal defect | 60 |
pulmonary vasculature | 59 |
patients undergoing | 59 |
oxygen saturation | 59 |
among patients | 58 |
external examination | 58 |
fl ow | 58 |
one patient | 58 |
submit samples | 57 |
patients treated | 57 |
pao fio | 57 |
obstructive lung | 57 |
pulmonary infection | 57 |
ct scan | 57 |
hypoxic pulmonary | 56 |
severe cases | 56 |
vena cava | 55 |
defense mechanisms | 55 |
infi ltration | 55 |
may lead | 55 |
respiratory infections | 55 |
artery pressure | 54 |
adhesion molecules | 54 |
weight loss | 54 |
respiratory diseases | 54 |
significant differences | 54 |
body weight | 54 |
patients admitted | 54 |
two patients | 54 |
patients may | 54 |
portal vein | 53 |
clinical manifestations | 53 |
alveolar epithelial | 53 |
hantavirus pulmonary | 53 |
ct findings | 53 |
ml min | 53 |
extracellular matrix | 53 |
patients receiving | 53 |
kg min | 52 |
diffuse interstitial | 52 |
viral infection | 52 |
clinical trial | 52 |
function tests | 52 |
clinical features | 52 |
present study | 51 |
cardiac index | 51 |
lymphoid tissue | 51 |
adverse effects | 51 |
pulmonary toxicity | 51 |
patients died | 51 |
lung tissues | 50 |
respiratory mechanics | 50 |
pulmonary capillary | 50 |
infected patients | 50 |
interstitial pneumonias | 50 |
pulmonary tuberculosis | 50 |
respiratory syncytial | 50 |
fi rst | 50 |
carbon monoxide | 49 |
acute exacerbations | 49 |
severe pulmonary | 49 |
rv failure | 49 |
clinical presentation | 49 |
blood gases | 49 |
health care | 49 |
hand column | 49 |
increased pulmonary | 49 |
commonly used | 49 |
cardiac arrest | 48 |
staphylococcus aureus | 48 |
nervous system | 48 |
air embolism | 48 |
infl ammatory | 48 |
secondary bacterial | 48 |
idiopathic interstitial | 48 |
first hours | 48 |
lung transplant | 48 |
rat lung | 48 |
aspiration pneumonia | 48 |
hyaline membranes | 48 |
clinical course | 47 |
study group | 47 |
statistical analysis | 47 |
pulmonary lesions | 47 |
alveolar hemorrhage | 47 |
peripheral blood | 46 |
basement membrane | 46 |
cardiopulmonary bypass | 46 |
interstitial pneumonitis | 46 |
blood loss | 46 |
ct scanning | 46 |
inflammatory cytokines | 46 |
chest radiographs | 46 |
ventilated patients | 46 |
blood volume | 45 |
fatty acids | 45 |
function testing | 45 |
pediatric patients | 45 |
cell lung | 45 |
chest tube | 45 |
influenza virus | 45 |
airway resistance | 45 |
fibrosing alveolitis | 45 |
syncytial virus | 45 |
inflammatory process | 45 |
laboratory animals | 45 |
lung volumes | 45 |
significant difference | 45 |
adult patients | 44 |
signifi cantly | 44 |
chronic pulmonary | 44 |
long term | 44 |
acquired pneumonia | 44 |
submit sample | 44 |
herpes simplex | 44 |
spinal cord | 44 |
lactate levels | 44 |
parenchymal changes | 44 |
ii pneumonocytes | 44 |
clinical practice | 44 |
procedures depend | 44 |
acute interstitial | 43 |
usual interstitial | 43 |
pulmonary angiography | 43 |
aged years | 43 |
cardiogenic shock | 43 |
allograft rejection | 43 |
small airways | 43 |
respiratory rate | 43 |
ground glass | 43 |
thoracic society | 43 |
immune system | 43 |
patients without | 42 |
congestive heart | 42 |
expiratory flow | 42 |
nasal mucosa | 42 |
lymph node | 42 |
retrospective study | 42 |
transplant recipients | 42 |
diabetes mellitus | 42 |
eosinophilic pneumonia | 41 |
viral pneumonia | 41 |
grossly identified | 41 |
pulmonary inflammation | 41 |
data suggest | 41 |
endothelial cell | 41 |
may develop | 41 |
blood fl | 41 |
heart surgery | 41 |
systemic vascular | 41 |
resolution ct | 41 |
effi cacy | 41 |
glass opacities | 41 |
may play | 41 |
pulmonary diseases | 41 |
postoperative period | 40 |
recent studies | 40 |
forced expiratory | 40 |
identified abnormalities | 40 |
pregnant women | 40 |
bronchopulmonary dysplasia | 40 |
lung fibrosis | 40 |
giant cells | 40 |
blood gas | 40 |
pulmonary hemorrhage | 40 |
persistent pulmonary | 40 |
alveolar macrophage | 40 |
artery catheter | 39 |
within hours | 39 |
underlying disease | 39 |
early stages | 39 |
preterm infants | 39 |
may contribute | 39 |
trauma patients | 39 |
physical examination | 39 |
pathological changes | 39 |
high altitude | 39 |
head injury | 39 |
two cases | 39 |
oxygen delivery | 39 |
pulmonary aspergillosis | 39 |
ejection fraction | 39 |
identifi ed | 39 |
mean arterial | 39 |
prognostic value | 39 |
randomized controlled | 39 |
mononuclear cells | 39 |
class i | 39 |
severe asthma | 39 |
high levels | 39 |
years old | 38 |
blood cells | 38 |
respiratory muscle | 38 |
high mortality | 38 |
lung compliance | 38 |
three patients | 38 |
pulmonary interstitial | 38 |
supplemental oxygen | 38 |
venous pressure | 38 |
orthotopic liver | 38 |
airway disease | 38 |
vascular endothelial | 38 |
severe ards | 38 |
ventricular failure | 38 |
alveolar space | 38 |
one case | 38 |
blood samples | 38 |
one study | 37 |
general population | 37 |
host disease | 37 |
lipid pneumonia | 37 |
cell hyperplasia | 37 |
natural history | 37 |
oxide synthase | 37 |
defi ned | 37 |
central nervous | 37 |
magnetic resonance | 37 |
common cause | 37 |
pulmonary involvement | 37 |
early stage | 37 |
related pulmonary | 37 |
mg dl | 36 |
lupus erythematosus | 36 |
diffi cult | 36 |
group ii | 36 |
survival rate | 36 |
pasteurella multocida | 36 |
lung inflammation | 36 |
atrial pressure | 36 |
vital capacity | 36 |
ventricular septal | 36 |
venous blood | 36 |
care units | 36 |
carinii pneumonia | 36 |
significantly lower | 36 |
lower airway | 36 |
mortality rates | 35 |
hiv infection | 35 |
immunodeficiency virus | 35 |
fatty acid | 35 |
cell proliferation | 35 |
free radicals | 35 |
respiratory infection | 35 |
also found | 35 |
left heart | 35 |
several studies | 35 |
systemic lupus | 35 |
oxygen species | 35 |
venous thromboembolism | 35 |
pseudomonas aeruginosa | 35 |
carbon dioxide | 35 |
icu stay | 35 |
antitrypsin deficiency | 35 |
heart catheterization | 35 |
ventricular dysfunction | 35 |
exercise capacity | 35 |
surface tension | 34 |
alveolar spaces | 34 |
ventilatory support | 34 |
bacterial infection | 34 |
arterial oxygen | 34 |
also known | 34 |
defi ne | 34 |
vascular smooth | 34 |
neutrophil elastase | 34 |
reactive oxygen | 34 |
copd exacerbations | 34 |
growth factors | 34 |
lung abscess | 34 |
streptococcus pneumoniae | 34 |
air pollution | 34 |
lung infections | 34 |
drug delivery | 34 |
lavage fluid | 33 |
ii score | 33 |
endotracheal tube | 33 |
plasma cells | 33 |
vascular tone | 33 |
wedge pressure | 33 |
lung allograft | 33 |
cor pulmonale | 33 |
high doses | 33 |
foreign body | 33 |
procedures described | 33 |
chronic respiratory | 33 |
vascular bed | 33 |
recent years | 33 |
disease progression | 33 |
red blood | 33 |
pediatric intensive | 33 |
tissue disease | 33 |
cell carcinoma | 32 |
idiopathic pneumonia | 32 |
may show | 32 |
pa thrombosis | 32 |
normal range | 32 |
many patients | 32 |
rmatively diagnosed | 32 |
infectious diseases | 32 |
systemic sclerosis | 32 |
laden macrophages | 32 |
disease severity | 32 |
pneumonia syndrome | 32 |
oxygen consumption | 32 |
transcription factor | 32 |
dry cough | 32 |
plasma levels | 32 |
multivariate analysis | 32 |
minute walk | 32 |
kg day | 32 |
muscle cell | 32 |
confi rmatively | 32 |
patients received | 32 |
ng ml | 32 |
secondary pulmonary | 32 |
proinflammatory cytokines | 32 |
pulmonary infiltrates | 32 |
poor prognosis | 32 |
pulmonary vessels | 32 |
small cell | 32 |
increased mortality | 31 |
significant increase | 31 |
oral cavity | 31 |
less common | 31 |
sleep apnea | 31 |
pulmonary pathology | 31 |
alveolar wall | 31 |
lung cancers | 31 |
cigarette smoking | 31 |
mucociliary clearance | 31 |
pressure support | 31 |
pneumonic mannheimiosis | 31 |
mast cells | 31 |
acute renal | 31 |
pleural space | 31 |
upper lobe | 31 |
year period | 31 |
patient aged | 31 |
ct scans | 31 |
induced acute | 31 |
severe sepsis | 31 |
pulmonary manifestations | 30 |
renal function | 30 |
lung mechanics | 30 |
mean pulmonary | 30 |
inferior vena | 30 |
cardiovascular disease | 30 |
plasminogen activator | 30 |
small pulmonary | 30 |
year survival | 30 |
pah patients | 30 |
world health | 30 |
jugular bulb | 30 |
large amounts | 30 |
immunodefi ciency | 30 |
consecutive patients | 30 |
may indicate | 30 |
young children | 30 |
gastrointestinal tract | 30 |
american thoracic | 30 |
upper lobes | 30 |
radiation therapy | 30 |
endothelial dysfunction | 30 |
mannheimia haemolytica | 30 |
portal hypertension | 30 |
human immunodeficiency | 30 |
clinical studies | 30 |
measured using | 29 |
immunocompromised patients | 29 |
myeloid cells | 29 |
imaging studies | 29 |
healthy controls | 29 |
early diagnosis | 29 |
fl aky | 29 |
premature infants | 29 |
respiratory health | 29 |
domestic animals | 29 |
inflammatory mediators | 29 |
middle lobe | 29 |
icu admission | 29 |
high incidence | 29 |
organ dysfunction | 29 |
blood transfusion | 29 |
diaphragmatic hernia | 29 |
chronic inflammation | 29 |
lesser extent | 29 |
adhesion molecule | 29 |
well tolerated | 29 |
emergency department | 29 |
clinical symptoms | 29 |
also cause | 29 |
ards patients | 29 |
health organization | 29 |
lung pathology | 29 |
airway epithelial | 29 |
widely used | 29 |
toxicologic study | 29 |
squamous metaplasia | 28 |
tract infections | 28 |
secondary prevention | 28 |
left ventricle | 28 |
vascular permeability | 28 |
cytokine production | 28 |
minute ventilation | 28 |
underlying lung | 28 |
ipf patients | 28 |
pulmonary delivery | 28 |
airflow limitation | 28 |
muscle weakness | 28 |
birth weight | 28 |
lung lobes | 28 |
venous thrombosis | 28 |
experimental studies | 28 |
enzootic pneumonia | 28 |
another study | 28 |
air leak | 28 |
clara cells | 28 |
positive end | 28 |
expiratory pressure | 28 |
bronchial epithelium | 28 |
patients showed | 28 |
functional residual | 27 |
pleural fluid | 27 |
systemic inflammatory | 27 |
results suggest | 27 |
surgical lung | 27 |
commonly seen | 27 |
respiratory society | 27 |
tyrosine kinase | 27 |
cryptogenic fibrosing | 27 |
ventricular function | 27 |
guinea pigs | 27 |
vein thrombosis | 27 |
case reports | 27 |
surfactant proteins | 27 |
severe respiratory | 27 |
receptor antagonist | 27 |
even though | 27 |
receptor expressed | 27 |
clinical data | 27 |
chest imaging | 27 |
systemic circulation | 27 |
desquamative interstitial | 27 |
cell histiocytosis | 27 |
cardiac function | 27 |
elderly patients | 27 |
alveolar septa | 27 |
vascular remodeling | 27 |
surfactant system | 27 |
acute bronchitis | 27 |
pathologic findings | 27 |
total lung | 27 |
amino acids | 27 |
respiratory function | 27 |
respiratory viruses | 27 |
muscular dystrophy | 27 |
breathing pattern | 27 |
european respiratory | 27 |
high concentrations | 27 |
oxygen therapy | 26 |
lower lobes | 26 |
atrial septal | 26 |
significantly increased | 26 |
th day | 26 |
chain reaction | 26 |
recent study | 26 |
suppurative bronchopneumonia | 26 |
heart defects | 26 |
polymerase chain | 26 |
chronic thromboembolic | 26 |
molecular weight | 26 |
occlusive disease | 26 |
specifi city | 26 |
epithelial cell | 26 |
transcription factors | 26 |
four patients | 26 |
chronic interstitial | 26 |
human pulmonary | 26 |
life support | 26 |
liver function | 26 |
predictive value | 26 |
closely related | 26 |
nitrogen dioxide | 26 |
protein kinase | 26 |
reactive protein | 26 |
airflow obstruction | 26 |
lung dcs | 26 |
left atrial | 26 |
fibrinous bronchopneumonia | 26 |
liver transplant | 26 |
gross lesions | 26 |
allergic alveolitis | 26 |
least one | 26 |
hyaline membrane | 26 |
increased levels | 26 |
acquired immunodeficiency | 26 |
fio ratio | 26 |
pleural cavity | 26 |
associated lymphoid | 26 |
platelet activation | 26 |
chronic gvhd | 25 |
septic patients | 25 |
lung damage | 25 |
hiv infected | 25 |
surgical patients | 25 |
classifi cation | 25 |
university hospital | 25 |
pulmonary emphysema | 25 |
air trapping | 25 |
hepatic failure | 25 |
high fever | 25 |
ii pneumocytes | 25 |
cardiac disease | 25 |
animal model | 25 |
risk score | 25 |
blood alcohol | 25 |
patients requiring | 25 |
mixed venous | 25 |
open heart | 25 |
five patients | 25 |
lower lobe | 25 |
ductus arteriosus | 25 |
pulmonary vasodilation | 25 |
studies suggest | 25 |
triggering receptor | 25 |
common causes | 25 |
pulmonary hypertensive | 25 |
right atrial | 25 |
lamellar bodies | 25 |
i pneumonocytes | 25 |
increased expression | 25 |
hematologic malignancies | 25 |
autopsy findings | 25 |
hospital mortality | 25 |
acute onset | 25 |
brain injury | 25 |
expiratory volume | 25 |
significant correlation | 25 |
lung surfactant | 25 |
prone position | 25 |
residual capacity | 25 |
cell types | 25 |
may help | 25 |
immunodeficiency syndrome | 25 |
extrinsic allergic | 24 |
halo sign | 24 |
time course | 24 |
higher mortality | 24 |
goblet cells | 24 |
large quantity | 24 |
early mobilization | 24 |
commonly found | 24 |
metabolic acidosis | 24 |
channel blockers | 24 |
alveolar capillaries | 24 |
inspiratory pressure | 24 |
eight patients | 24 |
airway smooth | 24 |
platelet count | 24 |
obliterans syndrome | 24 |
hilar lymph | 24 |
skin lesions | 24 |
cryptococcus neoformans | 24 |
high dose | 24 |
heart association | 24 |
mouse model | 24 |
cell membrane | 24 |
pilot study | 24 |
brain death | 24 |
artery disease | 24 |
scoring system | 24 |
anhepatic stage | 24 |
amniotic fluid | 24 |
major role | 24 |
immune cells | 24 |
pulmonary congestion | 24 |
normal subjects | 24 |
overall mortality | 24 |
pulmonary thromboembolism | 24 |
surfactant material | 24 |
oxygen tension | 24 |
altitude pulmonary | 24 |
collagen vascular | 24 |
cohort study | 24 |
cancer patients | 24 |
squamous cell | 24 |
diffuse lung | 24 |
cardiac failure | 24 |
pathologic features | 24 |
acute phase | 24 |
high frequency | 23 |
american heart | 23 |
oleic acid | 23 |
radiation pneumonitis | 23 |
acute myocardial | 23 |
parenteral nutrition | 23 |
diagnostic imaging | 23 |
murine model | 23 |
also may | 23 |
tricuspid regurgitation | 23 |
clinical significance | 23 |
disseminated intravascular | 23 |
year old | 23 |
healthy subjects | 23 |
lower lung | 23 |
coronavirus disease | 23 |
also occur | 23 |
granulomatous pneumonia | 23 |
fluid overload | 23 |
gastric contents | 23 |
beneficial effects | 23 |
obliterative bronchiolitis | 23 |
cell surface | 23 |
hsct recipients | 23 |
pulmonary venous | 23 |
supine position | 23 |
high resolution | 23 |
thoracic cavity | 23 |
diffi culty | 23 |
blood lactate | 23 |
respiratory epithelium | 23 |
significantly reduced | 23 |
interstitial emphysema | 23 |
pulmonary parenchyma | 23 |
public health | 23 |
microscopic examination | 23 |
cd cells | 23 |
renal disease | 23 |
matrix metalloproteinase | 23 |
cells may | 23 |
clinical characteristics | 23 |
venous return | 23 |
severe head | 23 |
stroke volume | 23 |
male patient | 23 |
inhaled protein | 23 |
well known | 23 |
noninfectious pulmonary | 22 |
endothelial growth | 22 |
bronchial wall | 22 |
disease may | 22 |
large cell | 22 |
ciliary dyskinesia | 22 |
matrix metalloproteinases | 22 |
infectious pulmonary | 22 |
lung fi | 22 |
survival rates | 22 |
chronic inflammatory | 22 |
converting enzyme | 22 |
evidence suggests | 22 |
logistic regression | 22 |
intravascular coagulation | 22 |
calcium channel | 22 |
pulmonary interstitium | 22 |
syndrome coronavirus | 22 |
lymphomatoid granulomatosis | 22 |
within days | 22 |
glass liked | 22 |
serum levels | 22 |
diffuse pulmonary | 22 |
right atrium | 22 |
severe disease | 22 |
stimulating factor | 22 |
chest radiography | 22 |
one hour | 22 |
pleural fl | 22 |
rv dysfunction | 22 |
mean values | 22 |
endotracheal intubation | 22 |
pa pressure | 22 |
low levels | 22 |
giant cell | 22 |
host defense | 22 |
asbestos exposure | 22 |
goblet cell | 22 |
healthy volunteers | 22 |
tissue sections | 22 |
aortic valve | 22 |
pulmonary injury | 22 |
airway hyperresponsiveness | 22 |
studied patients | 22 |
massive pulmonary | 22 |
often associated | 22 |
informed consent | 22 |
many years | 22 |
associated pneumonia | 22 |
body temperature | 22 |
hospitalized patients | 22 |
asbestos fibres | 22 |
three cases | 22 |
lung capacity | 22 |
three different | 22 |
collagen deposition | 22 |
early studies | 22 |
ii cell | 22 |
median age | 22 |
may require | 22 |
normal lung | 22 |
renal dysfunction | 21 |
cell death | 21 |
normal lungs | 21 |
wound healing | 21 |
partial pressure | 21 |
within minutes | 21 |
human disease | 21 |
ventricular ejection | 21 |
barr virus | 21 |
allogeneic hematopoietic | 21 |
follow procedures | 21 |
seven patients | 21 |
diffusing capacity | 21 |
environmental factors | 21 |
tobacco smoke | 21 |
tract infection | 21 |
cause pulmonary | 21 |
see table | 21 |
laboratory tests | 21 |
opportunistic infections | 21 |
higher risk | 21 |
traction bronchiectasis | 21 |
patients suffering | 21 |
disordered breathing | 21 |
inflammatory responses | 21 |
reduced lung | 21 |
dust pneumoconiosis | 21 |
asbestos bodies | 21 |
hemodynamic parameters | 21 |
selective pulmonary | 21 |
significant changes | 21 |
pulmonary capillaries | 21 |
age years | 21 |
asthmatic children | 21 |
intracranial hypertension | 21 |
langerhans cell | 21 |
many cases | 21 |
potential therapeutic | 21 |
abscess formation | 21 |
aortic arch | 21 |
radiographic findings | 21 |
chronic disease | 21 |
syndrome pulmonary | 21 |
muscle strength | 21 |
interlobular septa | 21 |
inhaled corticosteroids | 21 |
chest ct | 21 |
cell lymphoma | 21 |
medial hypertrophy | 21 |
lung development | 21 |
bronchial obstruction | 21 |
nasal passages | 21 |
natriuretic peptide | 21 |
epidermal growth | 21 |
spontaneous breathing | 21 |
liver failure | 21 |
plexiform lesions | 21 |
gas analysis | 21 |
gestational age | 21 |
fev fvc | 21 |
first days | 21 |
electron microscopic | 21 |
bronchial asthma | 21 |
bronchiolar epithelium | 21 |
lung cells | 21 |
lining fluid | 20 |
clinical outcome | 20 |
elevated pulmonary | 20 |
interstitial pulmonary | 20 |
nonspecific interstitial | 20 |
miliary tuberculosis | 20 |
pulmonary mechanics | 20 |
saps ii | 20 |
particulate matter | 20 |
light microscopy | 20 |
hospital stay | 20 |
right lung | 20 |
late onset | 20 |
determine whether | 20 |
study period | 20 |
diagnostic value | 20 |
methenamine silver | 20 |
classifi ed | 20 |
pulmonary vasodilator | 20 |
lipoid pneumonia | 20 |
higher incidence | 20 |
factor receptor | 20 |
inspired oxygen | 20 |
three groups | 20 |
emergency room | 20 |
bronchial mucosa | 20 |
superior vena | 20 |
stem cells | 20 |
bowel disease | 20 |
gold standard | 20 |
inflammatory bowel | 20 |
protective effect | 20 |
significant decrease | 20 |
phrenic nerve | 20 |
obliterans organizing | 20 |
cryptogenic organizing | 20 |
may provide | 20 |
resonance imaging | 20 |
subcutaneous emphysema | 20 |
mesenchymal transition | 20 |
airway volume | 20 |
important cause | 20 |
massive fibrosis | 20 |
conducting system | 20 |
dry powder | 20 |
inclusion bodies | 20 |
continuous infusion | 20 |
may increase | 20 |
vascular endothelium | 20 |
pleural surface | 20 |
systemic arterial | 20 |
poor outcome | 20 |
alveolar edema | 20 |
alveolar interstitium | 20 |
alveolar surfactant | 20 |
therapeutic strategies | 20 |
granulation tissue | 20 |
pulmonary surfactants | 20 |
infectious agents | 19 |
human alveolar | 19 |
elevated levels | 19 |
ill children | 19 |
jugular vein | 19 |
studies may | 19 |
molecular mechanisms | 19 |
congenital diaphragmatic | 19 |
innate immune | 19 |
following parameters | 19 |
take charge | 19 |
brain stem | 19 |
mitral valve | 19 |
animal studies | 19 |
control study | 19 |
ct features | 19 |
hemodynamic effects | 19 |
transplant patients | 19 |
forced vital | 19 |
monoclonal antibodies | 19 |
capillary hemangiomatosis | 19 |
prism score | 19 |
respiratory muscles | 19 |
receptor antagonists | 19 |
chronic cases | 19 |
controlled trials | 19 |
advanced stage | 19 |
artery smooth | 19 |
delivery vectors | 19 |
pulmonary toxoplasmosis | 19 |
lung infection | 19 |
negative pressure | 19 |
hemodynamic changes | 19 |
olfactory epithelium | 19 |
airway epithelium | 19 |
vascular diseases | 19 |
hepatic arterial | 19 |
related lung | 19 |
tidal volumes | 19 |
conventional therapy | 19 |
air spaces | 19 |
lung toxicity | 19 |
cell growth | 19 |
antibiotic therapy | 19 |
thromboembolic pulmonary | 19 |
membrane disease | 19 |
ct pulmonary | 19 |
inotropic support | 19 |
natural products | 19 |
nutritional support | 19 |
phase ii | 19 |
bal fluid | 19 |
reperfusion injury | 19 |
alveolar injury | 19 |
blood culture | 19 |
young adults | 19 |
dust exposure | 19 |
blood cultures | 19 |
pulmonary infiltrate | 19 |
ipah patients | 19 |
lung involvement | 19 |
granulomatous disease | 19 |
first described | 19 |
soft tissue | 19 |
refl ux | 19 |
respiratory disorders | 19 |
pulmonary macrophages | 19 |
lung growth | 19 |
mean duration | 19 |
studies using | 19 |
obstructive sleep | 19 |
allogeneic bone | 19 |
laryngeal closure | 19 |
exogenous lipid | 18 |
sudden death | 18 |
poorly understood | 18 |
chest distress | 18 |
medical history | 18 |
organ system | 18 |
new york | 18 |
severe hypoxemia | 18 |
drug administration | 18 |
danhong injection | 18 |
primary ciliary | 18 |
tubercle bacilli | 18 |
body mass | 18 |
treatment group | 18 |
statistical significance | 18 |
three major | 18 |
bronchointerstitial pneumonia | 18 |
endothelin receptor | 18 |
therapeutic agents | 18 |
may explain | 18 |
rna delivery | 18 |
cell cycle | 18 |
early phase | 18 |
microbiologic study | 18 |
severe chronic | 18 |
pulmonary aspiration | 18 |
energy expenditure | 18 |
invasive aspergillosis | 18 |
fat embolism | 18 |
treated patients | 18 |
cardiogenic pulmonary | 18 |
may become | 18 |
pulmonary drug | 18 |
phase transition | 18 |
cardiopulmonary disease | 18 |
histologic sections | 18 |
randomised controlled | 18 |
significantly different | 18 |
regression analysis | 18 |
surface area | 18 |
meconium aspiration | 18 |
disease control | 18 |
squamous epithelium | 18 |
simplex virus | 18 |
regional lymph | 18 |
large number | 18 |
least two | 18 |
ventilatory defect | 18 |
clinical implications | 18 |
associated lung | 18 |
intravenous administration | 18 |
bone morphogenetic | 18 |
infi ltrative | 18 |
aids complicated | 18 |
organising pneumonia | 18 |
one lung | 18 |
imaging fi | 18 |
hours later | 18 |
two types | 18 |
endogenous lipid | 18 |
clinical diagnosis | 18 |
lipid peroxidation | 18 |
mean sd | 18 |
critical illness | 18 |
included patients | 18 |
hepatic artery | 18 |
progressive massive | 18 |
large numbers | 18 |
respiratory bronchioles | 18 |
lung macrophages | 18 |
parenchymal lung | 18 |
chronic renal | 18 |
abdominal pain | 18 |
protein therapeutics | 18 |
escherichia coli | 18 |
acute eosinophilic | 18 |
fatal cases | 18 |
operating room | 18 |
pulmonary abscesses | 18 |
ciliated cells | 18 |
haemophilus influenzae | 18 |
study showed | 18 |
high morbidity | 18 |
first day | 18 |
literature review | 18 |
small airway | 18 |
clinical study | 18 |
risk patients | 18 |
class ii | 18 |
hematological malignancies | 18 |
respiratory insufficiency | 18 |
may produce | 18 |
pulmonary valve | 18 |
interstitial edema | 18 |
granuloma formation | 18 |
bronchial epithelial | 18 |
inhaled particles | 18 |
complications following | 18 |
flow rate | 17 |
must also | 17 |
disease process | 17 |
month period | 17 |
therapeutic approach | 17 |
inflammatory reaction | 17 |
rapidly progressive | 17 |
carotid artery | 17 |
bordetella bronchiseptica | 17 |
endothelial injury | 17 |
per minute | 17 |
term infants | 17 |
selected patients | 17 |
platelet aggregation | 17 |
newborn infants | 17 |
mean airway | 17 |
major cause | 17 |
pulmonary gas | 17 |
skeletal muscle | 17 |
failure due | 17 |
allogeneic hsct | 17 |
simplex viral | 17 |
alveolar structure | 17 |
imaging demonstrations | 17 |
i mhc | 17 |
vascular remodelling | 17 |
two different | 17 |
residual volume | 17 |
leading cause | 17 |
mycoplasma pneumoniae | 17 |
white blood | 17 |
also seen | 17 |
therapeutic intervention | 17 |
also reported | 17 |
pulmonary abnormalities | 17 |
naked rna | 17 |
fi brotic | 17 |
ray demonstrates | 17 |
hepatic dysfunction | 17 |
multinucleated giant | 17 |
atrial fibrillation | 17 |
community acquired | 17 |
exhaled nitric | 17 |
pulmonary dysfunction | 17 |
aspergillus fumigatus | 17 |
remains unknown | 17 |
prosthetic repair | 17 |
pressure ventilation | 17 |
associated pulmonary | 17 |
take place | 17 |
may present | 17 |
hepatic blood | 17 |
may affect | 17 |
may reveal | 17 |
systolic blood | 17 |
complement activation | 17 |
north america | 17 |
fulminant hepatic | 17 |
ipf uip | 17 |
authors declare | 17 |
computed tomographic | 17 |
lung epithelial | 17 |
older children | 17 |
lung tumors | 17 |
i min | 17 |
acute pancreatitis | 17 |
pulmonary changes | 17 |
relatively low | 17 |
rehabilitation program | 17 |
air bronchogram | 17 |
defi nitive | 17 |
alveolar lining | 17 |
allergic bronchopulmonary | 17 |
internal jugular | 17 |
autosomal dominant | 17 |
acute gvhd | 17 |
invasive pulmonary | 17 |
noninvasive ventilation | 17 |
transplantation pulmonary | 17 |
prospectively studied | 17 |
diffusion capacity | 17 |
toxic effects | 17 |
pulmonary veno | 17 |
guinea pig | 17 |
resolution computed | 17 |
vasodilator therapy | 17 |
tissue damage | 17 |
patients following | 17 |
pediatric ild | 17 |
familial primary | 17 |
fibroblast proliferation | 17 |
may represent | 17 |
equi infection | 17 |
performed using | 17 |
gene therapy | 17 |
hospital admission | 17 |
foreign bodies | 17 |
one year | 17 |
confi rmed | 17 |
bronchial arteries | 17 |
airway remodelling | 17 |
significant reduction | 17 |
marrow transplant | 17 |
nodular shadows | 16 |
left atrium | 16 |
factors associated | 16 |
left lung | 16 |
liquid crystalline | 16 |
surfactant synthesis | 16 |
prognostic factors | 16 |
immune complex | 16 |
may involve | 16 |
potassium channels | 16 |
interstitial infiltrates | 16 |
median survival | 16 |
functional class | 16 |
coronary arteries | 16 |
underlying conditions | 16 |
restrictive lung | 16 |
also present | 16 |
mass index | 16 |
crystalline phase | 16 |
telomere length | 16 |
ex vivo | 16 |
lung may | 16 |
hantavirus infection | 16 |
alveolar cells | 16 |
signaling pathway | 16 |
drug abuse | 16 |
enteral feeding | 16 |
worse prognosis | 16 |
national institutes | 16 |
conducting airways | 16 |
tissue factor | 16 |
eosinophilic lung | 16 |
acid aspiration | 16 |
treatment strategies | 16 |
pulmonary defense | 16 |
replacement therapy | 16 |
room air | 16 |
less severe | 16 |
record weight | 16 |
changes may | 16 |
great vessels | 16 |
clinical disease | 16 |
pulmonary nodules | 16 |
based study | 16 |
six patients | 16 |
case series | 16 |
ventricular hypertrophy | 16 |
potential role | 16 |
energy ct | 16 |
also occurs | 16 |
pulmonary parenchymal | 16 |
paranasal sinuses | 16 |
delivery system | 16 |
cardiopulmonary rehabilitation | 16 |
capillary permeability | 16 |
less commonly | 16 |
coal pneumoconiosis | 16 |
airways disease | 16 |
tissue oxygenation | 16 |
inflammatory changes | 16 |
ciency syndrome | 16 |
diagnostic criteria | 16 |
care medicine | 16 |
deep vein | 16 |
patients hospitalized | 16 |
infection may | 16 |
extracorporeal life | 16 |
days later | 16 |
mediastinal lymph | 16 |
hiv positive | 16 |
frailty syndrome | 16 |
signifi cance | 16 |
antigen challenge | 16 |
disease associated | 16 |
cell transplant | 16 |
care setting | 16 |
artery bypass | 16 |
vascular dysfunction | 16 |
surfactant replacement | 16 |
preschool children | 16 |
novel coronavirus | 16 |
epithelial injury | 16 |
first months | 16 |
task force | 16 |
physical therapy | 16 |
prepare roentgenograms | 16 |
infectious disease | 16 |
remains unclear | 16 |
lobar pneumonia | 16 |
fungal infection | 16 |
usually present | 16 |
increased airway | 16 |
infective endocarditis | 16 |
clinical relevance | 16 |
thrombolytic therapy | 16 |
clara cell | 16 |
heart transplantation | 16 |
lung lesions | 16 |
abdominal cavity | 16 |
drug reaction | 16 |
nasal discharge | 16 |
positive pressure | 16 |
probably due | 16 |
diffuse parenchymal | 15 |
pleuropulmonary blastoma | 15 |
surgery patients | 15 |
lung disorders | 15 |
hematopoietic cell | 15 |
canine distemper | 15 |
complications associated | 15 |
changes include | 15 |
blood cell | 15 |
significant improvement | 15 |
steady state | 15 |
pulmonary endothelial | 15 |
strauss syndrome | 15 |
muscular atrophy | 15 |
obstructive pneumonia | 15 |
two hours | 15 |
foam cells | 15 |
medical treatment | 15 |
three days | 15 |
defi nition | 15 |
terminal bronchioles | 15 |
impaired gas | 15 |
type iii | 15 |
ganz catheter | 15 |
molecular basis | 15 |
copd exacerbation | 15 |
soluble triggering | 15 |
pneumococcal pneumonia | 15 |
tension pneumothorax | 15 |
disease patients | 15 |
mycobacterium bovis | 15 |
drug toxicity | 15 |
paraquat poisoning | 15 |
immunosuppressive therapy | 15 |
specific antibody | 15 |
kidney failure | 15 |
oxygen extraction | 15 |
related diseases | 15 |
visceral pleura | 15 |
overall survival | 15 |
autopsy procedures | 15 |
defense mechanism | 15 |
molecular pathology | 15 |
glass opacity | 15 |
catamenial pneumothorax | 15 |
pulmonary emboli | 15 |
chronic hypoxia | 15 |
lung lavage | 15 |
qs qt | 15 |
surgical icu | 15 |
deep venous | 15 |
paediatric intensive | 15 |
ciency virus | 15 |
ischemic heart | 15 |
surfactant abnormalities | 15 |
previous studies | 15 |
may include | 15 |
animal species | 15 |
clinical outcomes | 15 |
venovenous bypass | 15 |
urine output | 15 |
restrictive ventilatory | 15 |
wide variety | 15 |
autopsy studies | 15 |
respiratory support | 15 |
pulmonary veins | 15 |
mean value | 15 |
pressure overload | 15 |
injury induced | 15 |
american association | 15 |
bacterial pathogens | 15 |
short term | 15 |
died within | 15 |
surface viscosity | 15 |
pulmonary tissue | 15 |
patients required | 15 |
innate immunity | 15 |
alveolar surface | 15 |
high prevalence | 15 |
chronic heart | 15 |
mycobacterium avium | 15 |
amino acid | 15 |
chronic graft | 15 |
cause severe | 15 |
nutritional status | 15 |
endoplasmic reticulum | 15 |
increased incidence | 15 |
vascular changes | 15 |
cancer cells | 15 |
scanning demonstrates | 15 |
factors include | 15 |
tidal breathing | 15 |
respiratory problems | 15 |
will also | 15 |
section ct | 15 |
sickle cell | 15 |
rhinovirus infection | 15 |
united kingdom | 15 |
vasoactive intestinal | 15 |
independent predictor | 15 |
small nodules | 15 |
pulmonary hemodynamics | 15 |
multiple trauma | 15 |
superoxide dismutase | 15 |
type unspecified | 15 |
cerebral blood | 15 |
primary lung | 15 |
class iii | 15 |
lymphatic vessels | 15 |
part ii | 15 |
sample size | 15 |
gram stain | 15 |
alveolar capillary | 15 |
surfactant therapy | 15 |
american college | 15 |
recurrent pneumothorax | 15 |
pulmonary lymphoma | 15 |
coagulation factors | 15 |
dead space | 15 |
increased production | 15 |
organ systems | 15 |
particle size | 15 |
collagen synthesis | 15 |
mg day | 15 |
positive blood | 15 |
occupational asthma | 15 |
atrophic rhinitis | 15 |
imaging findings | 15 |
symptoms include | 15 |
fi elds | 15 |
skin test | 15 |
alveolar air | 15 |
two major | 15 |
univariate analysis | 15 |
glass attenuation | 15 |
malignant mesothelioma | 15 |
surgical procedures | 15 |
experimental animals | 15 |
severe pneumonia | 15 |
onset noninfectious | 15 |
blood vessel | 14 |
patient population | 14 |
environmental exposures | 14 |
mtb infection | 14 |
diagnostic accuracy | 14 |
dust particles | 14 |
allergic asthma | 14 |
caseous necrosis | 14 |
neuromuscular disorders | 14 |
distemper virus | 14 |
like growth | 14 |
epithelial lining | 14 |
response syndrome | 14 |
conventional mechanical | 14 |
equine influenza | 14 |
metabolic syndrome | 14 |
pediatric pulmonary | 14 |
airway pressures | 14 |
chronic airway | 14 |
randomized trial | 14 |
morphogenetic protein | 14 |
toxoplasma gondii | 14 |
hydrogen peroxide | 14 |
human immunodefi | 14 |
medical therapy | 14 |
one week | 14 |
previously described | 14 |
severity score | 14 |
national heart | 14 |
drug therapy | 14 |
acute rejection | 14 |
south africa | 14 |
disease caused | 14 |
two main | 14 |
pulmonary pressure | 14 |
hepatorenal syndrome | 14 |
pregnant patients | 14 |
surfactant phospholipids | 14 |
patients compared | 14 |
mediastinal lymphadenectasis | 14 |
chemotherapeutic agents | 14 |
first years | 14 |
neuroendocrine cell | 14 |
duchenne muscular | 14 |
experimental study | 14 |
independently associated | 14 |
blood institute | 14 |
serious complications | 14 |
corticosteroid therapy | 14 |
special stains | 14 |
bronchial secretions | 14 |
ventilation perfusion | 14 |
lymphocytic interstitial | 14 |
chronic cough | 14 |
hypertension associated | 14 |
lung immunity | 14 |
mucus production | 14 |
microscopic lesions | 14 |
first week | 14 |
progressive pulmonary | 14 |
cardiac transplantation | 14 |
controlled study | 14 |
bronchopulmonary aspergillosis | 14 |
independent predictors | 14 |
single dose | 14 |
bronchogram sign | 14 |
middle east | 14 |
mountain sickness | 14 |
critical role | 14 |
internal carotid | 14 |
lung carcinoma | 14 |
pulmonary eosinophilia | 14 |
lymphoproliferative disorders | 14 |
humoral immunity | 14 |
tracheobronchial tree | 14 |
pathologic changes | 14 |
clinical application | 14 |
injury caused | 14 |
increased plasma | 14 |
respiratory pathogens | 14 |
rv tlc | 14 |
increased significantly | 14 |
varying degrees | 14 |
inflammatory cell | 14 |
normal pulmonary | 14 |
streptococcus equi | 14 |
liked shadows | 14 |
main cause | 14 |
productive cough | 14 |
requiring mechanical | 14 |
drug reactions | 14 |
guttural pouch | 14 |
pneumocystis pneumonia | 14 |
possible causes | 14 |
ascending aorta | 14 |
different types | 14 |
takes place | 14 |
circulatory support | 14 |
central type | 14 |
urea nitrogen | 14 |
peripheral lung | 14 |
cell function | 14 |
herpes virus | 14 |
smoke inhalation | 14 |
lung parenchymal | 14 |
two years | 14 |
severe copd | 14 |
foreign material | 14 |
alveolar fibrosis | 14 |
asthmatic patients | 14 |
cell migration | 14 |
large fl | 14 |
fetal lung | 14 |
allergic rhinitis | 14 |
atypical pneumonia | 14 |
alveolar hypoxia | 14 |
air leaks | 14 |
portal venous | 14 |
inflammatory effects | 14 |
may improve | 14 |
monoclonal antibody | 14 |
experimental model | 14 |
average age | 14 |
oxygen toxicity | 14 |
acute kidney | 14 |
silver stain | 14 |
good correlation | 14 |
pneumocystis jiroveci | 14 |
germline mutations | 14 |
fatal outcome | 14 |
endothelial damage | 14 |
mononuclear cell | 14 |
rarely seen | 14 |
needle aspiration | 14 |
syndrome caused | 14 |
cant difference | 14 |
cellular debris | 14 |
positive patients | 14 |
delivery systems | 14 |
per year | 14 |
lymphoid interstitial | 14 |
exercise tolerance | 14 |
fibrosis pulmonary | 14 |
preventive measures | 14 |
later stages | 14 |
clinical use | 13 |
decreased significantly | 13 |
vitro studies | 13 |
intratracheal administration | 13 |
respiratory viral | 13 |
fibrotic lung | 13 |
ml vs | 13 |
working group | 13 |
metabolic alkalosis | 13 |
multiple myeloma | 13 |
campbell syndrome | 13 |
muscle activities | 13 |
conscious rats | 13 |
general anesthesia | 13 |
may appear | 13 |
free survival | 13 |
hemolytic uremic | 13 |
vascular wall | 13 |
ali ards | 13 |
manifestations include | 13 |
function test | 13 |
nonproductive cough | 13 |
increased numbers | 13 |
care patients | 13 |
renal syndrome | 13 |
animal experiments | 13 |
recent advances | 13 |
routinely used | 13 |
pulmonary neoplasms | 13 |
group iii | 13 |
pulmonary symptoms | 13 |
post hsct | 13 |
supportive care | 13 |
cell lines | 13 |
previously healthy | 13 |
pulmonary neuroendocrine | 13 |
early detection | 13 |
coronary heart | 13 |
often present | 13 |
rib cage | 13 |
tobacco smoking | 13 |
pulmonary system | 13 |
pressure mmhg | 13 |
clinical management | 13 |
fi stula | 13 |
knockout mice | 13 |
thoracic surgery | 13 |
pa endothelium | 13 |
pain management | 13 |
hepatic encephalopathy | 13 |
postoperative pulmonary | 13 |
basal cells | 13 |
rat alveolar | 13 |
immunocompromised hosts | 13 |
suspected pulmonary | 13 |
airway infl | 13 |
extensively studied | 13 |
term exposure | 13 |
first postoperative | 13 |
plasma proteins | 13 |
lesions may | 13 |
much higher | 13 |
type pneumocytes | 13 |
laboratory findings | 13 |
leak syndrome | 13 |
underlying condition | 13 |
disease pulmonary | 13 |
ml cm | 13 |
nine patients | 13 |
cut surface | 13 |
mediated immunity | 13 |
th cells | 13 |
heart strain | 13 |
immune status | 13 |
may decrease | 13 |
natural killer | 13 |
molecular biology | 13 |
peak inspiratory | 13 |
pulse oximetry | 13 |
filtration rate | 13 |
pulmonary thrombosis | 13 |
wide range | 13 |
immune complexes | 13 |
oxygenation index | 13 |
parietal pleura | 13 |
inclusion criteria | 13 |
significantly improved | 13 |
scoring systems | 13 |
first month | 13 |
continuous intravenous | 13 |
neonatal respiratory | 13 |
cells within | 13 |
gastroesophageal reflux | 13 |
pathogenic bacteria | 13 |
peak expiratory | 13 |
constant flow | 13 |
histoplasma capsulatum | 13 |
newborn lambs | 13 |
solid organ | 13 |
colleagues found | 13 |
kv channels | 13 |
cystic lesions | 13 |
tumor cells | 13 |
gefi tinib | 13 |
parainfluenza virus | 13 |
see disease | 13 |
medical records | 13 |
controlled clinical | 13 |
intercellular adhesion | 13 |
age groups | 13 |
exacerbation events | 13 |
ventricular septum | 13 |
inducible nitric | 13 |
invasive fungal | 13 |
imaging modality | 13 |
pneumonia may | 13 |
tracheal pressure | 13 |
clot formation | 13 |
following cardiac | 13 |
autopsy study | 13 |
nursing staff | 13 |
central role | 13 |
clinical investigations | 13 |
intubated patients | 13 |
protective ventilation | 13 |
activated protein | 13 |
pulmonary disorders | 13 |
fatal pulmonary | 13 |
cytomegalovirus pneumonia | 13 |
tuberculosis infection | 13 |
renal replacement | 13 |
mitral stenosis | 13 |
increased susceptibility | 13 |
structural changes | 13 |
improved survival | 13 |
strongyloides stercoralis | 13 |
several days | 13 |
ii alveolar | 13 |
pericardial effusion | 13 |
frequently used | 13 |
lymph vessels | 13 |
low birth | 13 |
ultrastructural study | 13 |
age group | 13 |
pulmonary immune | 13 |
increased vascular | 13 |
associated ild | 13 |
studies showed | 13 |
tissue plasminogen | 13 |
right middle | 13 |
linear regression | 13 |
oxygen radicals | 13 |
following treatment | 13 |
tricuspid valve | 13 |
exclusion criteria | 13 |
liver cirrhosis | 13 |
relative risk | 13 |
bronchial pneumonia | 13 |
infections may | 13 |
myocardial oxygen | 13 |
exercise testing | 13 |
white matter | 13 |
breast cancer | 13 |
histologic features | 13 |
clinical conditions | 13 |
septal thickening | 13 |
venoocclusive disease | 13 |
patients infected | 13 |
transbronchial biopsy | 13 |
white cell | 13 |
antibody response | 13 |
will help | 13 |
current concepts | 13 |
continuous monitoring | 13 |
tube thoracostomy | 13 |
disease following | 13 |
polyarteritis nodosa | 13 |
assisted ventilation | 13 |
avium complex | 13 |
myocardial ischemia | 13 |
macrophage activation | 13 |
mechanical properties | 13 |
intestinal peptide | 13 |
glasgow coma | 13 |
serologic studies | 13 |
brain damage | 13 |
blood eosinophilia | 13 |
support ventilation | 13 |
care med | 13 |
murine models | 13 |
basic anomaly | 13 |
capillary wedge | 13 |
acute inflammatory | 13 |
day mortality | 13 |
cell carcinomas | 13 |
granulomatous inflammation | 13 |
early postoperative | 13 |
inhibitory effect | 13 |
walk test | 13 |
cause mortality | 13 |
thromboembolic disease | 13 |
sectional area | 13 |
femoral vein | 13 |
thrombotic thrombocytopenic | 13 |
rheumatoid factor | 13 |
bioactive compounds | 12 |
biliary atresia | 12 |
advanced disease | 12 |
angiotensin ii | 12 |
pulmonary stenosis | 12 |
chester disease | 12 |
mast cell | 12 |
tissue culture | 12 |
pg kg | 12 |
change significantly | 12 |
air pollutants | 12 |
prognostic significance | 12 |
mg ml | 12 |
valvular heart | 12 |
tumour necrosis | 12 |
icu syndrome | 12 |
kidney disease | 12 |
first year | 12 |
situ hybridization | 12 |
treatment modalities | 12 |
second group | 12 |
systemic symptoms | 12 |
life cycle | 12 |
may reduce | 12 |
alveolar ducts | 12 |
old male | 12 |
ta activity | 12 |
inflammatory lung | 12 |
fibrosis induced | 12 |
also reduced | 12 |
normal individuals | 12 |
significantly decreased | 12 |
pediatric icu | 12 |
ventilator settings | 12 |
bile ducts | 12 |
total pulmonary | 12 |
submucosal glands | 12 |
low dose | 12 |
patient care | 12 |
wall thickness | 12 |
degradation products | 12 |
well described | 12 |
ros production | 12 |
prone positioning | 12 |
transplant candidates | 12 |
low cardiac | 12 |
commercially available | 12 |
bed rest | 12 |
hematologic malignancy | 12 |
nuclear factor | 12 |
taken together | 12 |
stroke rehabilitation | 12 |
independent risk | 12 |
elastic recoil | 12 |
flail chest | 12 |
transesophageal echocardiography | 12 |
frozen sections | 12 |
neonatal period | 12 |
cell membranes | 12 |
pleural disease | 12 |
intravascular macrophages | 12 |
significant role | 12 |
infectious complications | 12 |
ats ers | 12 |
total respiratory | 12 |
standard deviation | 12 |
children aged | 12 |
enteral nutrition | 12 |
uremic syndrome | 12 |
air barrier | 12 |
capillary endothelium | 12 |
listeria monocytogenes | 12 |
airway remodeling | 12 |
mineral oil | 12 |
cardiac catheterization | 12 |
host response | 12 |
various forms | 12 |
oral administration | 12 |
asbestos fibers | 12 |
clinical findings | 12 |
genetic mutations | 12 |
one third | 12 |
primary spontaneous | 12 |
odds ratio | 12 |
pah due | 12 |
patients underwent | 12 |
protective effects | 12 |
analysis showed | 12 |
total body | 12 |
also increased | 12 |
spinal muscular | 12 |
nasogastric tube | 12 |
female patient | 12 |
dependent manner | 12 |
significantly less | 12 |
tropical pulmonary | 12 |
open lung | 12 |
steroid therapy | 12 |
also contribute | 12 |
body fluids | 12 |
mycoplasma hyopneumoniae | 12 |
medical center | 12 |
airway hyperreactivity | 12 |
last years | 12 |
showed significant | 12 |
phagocytic cells | 12 |
cell adhesion | 12 |
mineral dust | 12 |
another important | 12 |
intracranial pressure | 12 |
stress may | 12 |
new insights | 12 |
free radical | 12 |
blood coagulation | 12 |
fi beroptic | 12 |
body irradiation | 12 |
rat model | 12 |
urinary bladder | 12 |
preliminary results | 12 |
several weeks | 12 |
ischemia reperfusion | 12 |
pulmonary abscess | 12 |
several years | 12 |
ccb group | 12 |
alcohol concentration | 12 |
surgical treatment | 12 |
vascular resistances | 12 |
risk assessment | 12 |
experimental models | 12 |
cell disease | 12 |
two distinct | 12 |
lung infiltrates | 12 |
data analysis | 12 |
fast bacilli | 12 |
bacterial meningitis | 12 |
tertiary care | 12 |
may take | 12 |
airways obstruction | 12 |
lobe syndrome | 12 |
postoperative day | 12 |
important factor | 12 |
inspired air | 12 |
systolic pressure | 12 |
macrophage colony | 12 |
also shown | 12 |
secondary forms | 12 |
airway function | 12 |
excessive activation | 12 |
aspiration syndrome | 12 |
lymphoid hyperplasia | 12 |
activating factor | 12 |
three times | 12 |
therapeutic approaches | 12 |
international society | 12 |
guttural pouches | 12 |
dissection techniques | 12 |
autologous blood | 12 |
health status | 12 |
rare disease | 12 |
hypertension pulmonary | 12 |
sepsis syndrome | 12 |
often fatal | 12 |
practice guidelines | 12 |
data collection | 12 |
also showed | 12 |
disease due | 12 |
feeding tube | 12 |
malt lymphoma | 12 |
also associated | 12 |
assessed using | 12 |
severe pah | 12 |
following allogeneic | 12 |
mouse lung | 12 |
surgical management | 12 |
kidney injury | 12 |
cancer risk | 12 |
significant change | 12 |
systemic inflammation | 12 |
langerhans cells | 12 |
causative agent | 12 |
remained unchanged | 12 |
two forms | 12 |
often accompanied | 12 |
intrathoracic pressure | 12 |
higher levels | 12 |
room temperature | 12 |
blurry boundaries | 12 |
nk cells | 12 |
sputum production | 12 |
predisposing factors | 12 |
flow pattern | 12 |
pulmonary inflammatory | 12 |
ductal artery | 12 |
surgical procedure | 12 |
bronchial tree | 12 |
long periods | 12 |
vital signs | 12 |
per day | 12 |
severity scores | 12 |
pulmonary venoocclusive | 12 |
vascular beds | 11 |
developing countries | 11 |
organ transplantation | 11 |
small vessels | 11 |
toxicologic sampling | 11 |
study found | 11 |
patients survived | 11 |
fi eld | 11 |
common pathogens | 11 |
pa pressures | 11 |
peep level | 11 |
third trimester | 11 |
antibody production | 11 |
gold stage | 11 |
renal transplantation | 11 |
ankylosing spondylitis | 11 |
primary pht | 11 |
study pulmonary | 11 |
primary disease | 11 |
arterial ph | 11 |
major pulmonary | 11 |
test probability | 11 |
inspiratory muscle | 11 |
ciliated epithelium | 11 |
chest computed | 11 |
rehabilitation programs | 11 |
also noted | 11 |
adrenal glands | 11 |
simple aspiration | 11 |
workers exposed | 11 |
free fatty | 11 |
retinoic acid | 11 |
hematogenous dissemination | 11 |
low grade | 11 |
disease progresses | 11 |
general dissection | 11 |
myalgia syndrome | 11 |
early treatment | 11 |
complete resolution | 11 |
whole body | 11 |
deficient mice | 11 |
systemic disease | 11 |
olfactory mucosa | 11 |
term effects | 11 |
different levels | 11 |
myocardial depression | 11 |
clinical history | 11 |
neuromuscular blockade | 11 |
lung lymphocytes | 11 |
features include | 11 |
bronchial artery | 11 |
oxygen transport | 11 |
cerebrospinal fluid | 11 |
exogenous surfactant | 11 |
tissue injury | 11 |
tissue perfusion | 11 |
adverse drug | 11 |
tissue samples | 11 |
two days | 11 |
puuv rna | 11 |
underlying etiology | 11 |
hypertension secondary | 11 |
injury following | 11 |
treatment options | 11 |
venous system | 11 |
successful treatment | 11 |
prepare photographs | 11 |
caval anastomosis | 11 |
year follow | 11 |
bronchial walls | 11 |
term use | 11 |
pathogenetic mechanisms | 11 |
idiopathic pah | 11 |
hemorrhagic shock | 11 |
surfactant production | 11 |
iv molecular | 11 |
inhibitory effects | 11 |
resource utilization | 11 |
mycoplasma pneumonia | 11 |
infi ltrates | 11 |
national health | 11 |
chronic kidney | 11 |
low risk | 11 |
sin nombre | 11 |
childhood asthma | 11 |
systemic hypotension | 11 |
life expectancy | 11 |
foamy macrophages | 11 |
multiple nodules | 11 |
findings suggest | 11 |
stable copd | 11 |
total number | 11 |
examination reveals | 11 |
income countries | 11 |
neuroendocrine cells | 11 |
early childhood | 11 |
include cough | 11 |
pde inhibitors | 11 |
induced sputum | 11 |
low tidal | 11 |
arachidonic acid | 11 |
common symptoms | 11 |
van gieson | 11 |
ultrastructural examination | 11 |
pulmonary infarction | 11 |
emergency medical | 11 |
less likely | 11 |
clinical picture | 11 |
hemodynamic instability | 11 |
progenitor cells | 11 |
heterogeneous group | 11 |
purulent sputum | 11 |
induced emphysema | 11 |
reportable disease | 11 |
oxygen supply | 11 |
vast majority | 11 |
decompression sickness | 11 |
prospective studies | 11 |
smoking cessation | 11 |
gene silencing | 11 |
gastric acid | 11 |
human body | 11 |
key role | 11 |
hemodynamic status | 11 |
xanthine oxidase | 11 |
penicillium marneffei | 11 |
british thoracic | 11 |
also important | 11 |
randomized study | 11 |
lung health | 11 |
culty breathing | 11 |
ten patients | 11 |
glutathione levels | 11 |
clinical settings | 11 |
extracorporeal circulation | 11 |
peripheral vascular | 11 |
fibroblastic foci | 11 |
signaling pathways | 11 |
upper airways | 11 |
mean time | 11 |
occlusion pressure | 11 |
pulmonary markings | 11 |
also show | 11 |
histological changes | 11 |
sputum culture | 11 |
fibrosis patients | 11 |
lactate dehydrogenase | 11 |
alveolar lavage | 11 |
thoracic aorta | 11 |
volume overload | 11 |
patients whose | 11 |
airway wall | 11 |
trx inhibits | 11 |
high level | 11 |
immune function | 11 |
wbc count | 11 |
study included | 11 |
silica particles | 11 |
moist rales | 11 |
infrahepatic ivc | 11 |
intravenous epoprostenol | 11 |
diagnostic tests | 11 |
matrix deposition | 11 |
air bronchograms | 11 |
sirna delivery | 11 |
prostacyclin analogue | 11 |
part iv | 11 |
major surgery | 11 |
severely affected | 11 |
mucociliary escalator | 11 |
arterial flow | 11 |
strongly associated | 11 |
cause lung | 11 |
therapeutic effect | 11 |
specific proteins | 11 |
expiratory time | 11 |
red cell | 11 |
asbestos workers | 11 |
small number | 11 |
nyha class | 11 |
consensus conference | 11 |
autopsy cases | 11 |
diseases including | 11 |
fibrosis lung | 11 |
thrombocytopenic purpura | 11 |
transmission electron | 11 |
beryllium disease | 11 |
placebo group | 11 |
much lower | 11 |
following hematopoietic | 11 |
smoking history | 11 |
antibiotic treatment | 11 |
blood glucose | 11 |
acute leukemia | 11 |
may contain | 11 |
syndrome associated | 11 |
parasitic lung | 11 |
late stages | 11 |
risk group | 11 |
pa branches | 11 |
past years | 11 |
low lung | 11 |
transgenic mice | 11 |
pleural adhesions | 11 |
systemic diseases | 11 |
telomere shortening | 11 |
pulmonary haemodynamics | 11 |
inspiratory time | 11 |
lamina propria | 11 |
hospital discharge | 11 |
bacterial pneumonias | 11 |
group showed | 11 |
tissue destruction | 11 |
term survival | 11 |
plasma lactate | 11 |
parenchymal disease | 11 |
positive airway | 11 |
cmv pneumonia | 11 |
right side | 11 |
acute severe | 11 |
infectious origin | 11 |
alcoholic liver | 11 |
shear stress | 11 |
without significant | 11 |
patients studied | 11 |
scanning electron | 11 |
surgical intervention | 11 |
occupational exposure | 11 |
inducible factor | 11 |
also involved | 11 |
million people | 11 |
pulsed doppler | 11 |
severe infections | 11 |
affected lungs | 11 |
genetic factors | 11 |
inflammatory effect | 11 |
lymphoid cells | 11 |
candida albicans | 11 |
disease exacerbations | 11 |
occasionally seen | 11 |
conditioning regimens | 11 |
suspected underlying | 11 |
several factors | 11 |
hypertensive disorders | 11 |
dilated cardiomyopathy | 11 |
disease states | 11 |
pleural thickening | 11 |
older adults | 11 |
advanced stages | 11 |
pulmonic valve | 11 |
term follow | 11 |
cell counts | 11 |
pulmonary blastoma | 11 |
vascular reactivity | 11 |
risk stratification | 11 |
derived growth | 11 |
adrenal insufficiency | 11 |
record extent | 11 |
postoperative complications | 11 |
five cases | 11 |
autosomal recessive | 11 |
normal values | 11 |
rescue therapy | 11 |
hemorrhagic fever | 11 |
grade fever | 11 |
large airways | 11 |
fi nding | 11 |
postmortem examination | 11 |
postural changes | 11 |
map mmhg | 11 |
mpm ii | 11 |
immune mechanisms | 11 |
thyroid transcription | 10 |
surgical interventions | 10 |
may vary | 10 |
artery pressures | 10 |
plasma concentrations | 10 |
endovascular therapy | 10 |
lower extremities | 10 |
rna therapeutics | 10 |
transthoracic needle | 10 |
patients developed | 10 |
time period | 10 |
death due | 10 |
dynamic compliance | 10 |
respiratory acidosis | 10 |
current knowledge | 10 |
hemodynamic monitoring | 10 |
aspiration pneumonitis | 10 |
patient populations | 10 |
respiratory mucosa | 10 |
thrombus formation | 10 |
findings may | 10 |
inspiratory flow | 10 |
autoimmune disease | 10 |
talc pleurodesis | 10 |
mrna expression | 10 |
findings include | 10 |
exercise training | 10 |
decreased pulmonary | 10 |
see syndrome | 10 |
global strategy | 10 |
burned patients | 10 |
tumor suppressor | 10 |
retropharyngeal lymph | 10 |
nodular opacities | 10 |
rv contractility | 10 |
immediate postoperative | 10 |
machine learning | 10 |
anaerobic bacteria | 10 |
myristate acetate | 10 |
volume curve | 10 |
bilateral pneumothoraces | 10 |
small molecule | 10 |
ct angiography | 10 |
identify patients | 10 |
rats exposed | 10 |
usually occurs | 10 |
cystic adenomatoid | 10 |
syndrome following | 10 |
novel therapies | 10 |
allergic airway | 10 |
among others | 10 |
tube drainage | 10 |
mediated lung | 10 |
may prove | 10 |
therapeutic activity | 10 |
fi broblasts | 10 |
clinical value | 10 |
different forms | 10 |
exact test | 10 |
may induce | 10 |
one lobe | 10 |
expiratory ta | 10 |
surface active | 10 |
pregnant patient | 10 |
viral antigen | 10 |
hydrochloric acid | 10 |
two studies | 10 |
renal insufficiency | 10 |
whole blood | 10 |
healthy individuals | 10 |
plasma fibrinogen | 10 |
airway reactivity | 10 |
chest trauma | 10 |
patients diagnosed | 10 |
lipid metabolism | 10 |
european society | 10 |
cerebral perfusion | 10 |
wall thickening | 10 |
tube placement | 10 |
patients develop | 10 |
new zealand | 10 |
broad spectrum | 10 |
murine lung | 10 |
fibroblast growth | 10 |
intermediate hosts | 10 |
respiratory complications | 10 |
diastolic pressure | 10 |
small amounts | 10 |
nucleic acid | 10 |
hemolytic anemia | 10 |
respiratory status | 10 |
fatty changes | 10 |
two drugs | 10 |
inhalation therapy | 10 |
untreated patients | 10 |
infl uence | 10 |
healthy people | 10 |
consensus statement | 10 |
therapeutic options | 10 |
bilateral ground | 10 |
imaging demonstrates | 10 |
undergoing liver | 10 |
intratracheal instillation | 10 |
ct fi | 10 |
chemically induced | 10 |
accessory cell | 10 |
heart chambers | 10 |
pulmonary complication | 10 |
portopulmonary hypertension | 10 |
ethics committee | 10 |
signal transduction | 10 |
muc ac | 10 |
miliary nodules | 10 |
edema may | 10 |
ra pressure | 10 |
larva migrans | 10 |
include pulmonary | 10 |
retrospective analysis | 10 |
antigen detection | 10 |
fischer rats | 10 |
soft tissues | 10 |
lipoic acid | 10 |
often used | 10 |